Widely reported research published last week in the medical journal The Lancet spells good news for the Massachusetts-based Advanced Cell Technology (ACT) and its emerging retinal-disease treatment. Results from two early clinical trials indicate there were no serious adverse events associated with its stem-cell-derived therapy. Also, it appeared to improve vision in some patients with two kinds of macular
The 2018 Foundation Fighting Blindness Conference – Visions2018 – will be held at the Sheraton San Diego Hotel and Marina, San Diego, California, June 21 – 23, 2018.
The development program for a new drug with the potential to treat a common form of autosomal dominant retinitis pigmentosa (adRP) has received a boost with Shire’s acquisition of BIKAM Pharmaceuticals, the original developer of the experimental treatment.
The Foundation Fighting Blindness Clinical Research Institute (FFB CRI) has completed patient enrollment for its Phase II clinical trial for valproic acid, a therapy which has shown some suggestion of slowing loss of visual function in people with autosomal dominant retinitis pigmentosa (adRP). Valproic acid was previously approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizure disorders. The 90-participant study of valproic acid for people with confirmed adRP was
This is not an easy time. FFB offers all the information and support you need.
People affected by retinal diseases tell their stories.
Learn how to participate in FFB’s signature 5K event, taking place nationwide.
Your eyes are not just windows to your soul, but to your health as well
The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. A cure is in sight and you can help us reach it.